Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Ruth M McKernan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chair of the Scientific Advisory Board of the Dementia Goals Programme, Operating Partner of SV Health Investors, London, UK. Hauptthemen laut MEDLINE: Dementia, Clinical Trials as Topic, Health Services Accessibility. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Wellcome Trust, NIHR Cambridge Biomedical Research Centre.
Themen: Demenz
Abstract (Originalsprache)
The Dame Barbara Windsor Dementia Goals Programme was launched by the UK Government to accelerate the development and delivery of new treatments for dementia. We present the recommendations from the Scientific Advisory Board, to enable timely access to therapies for the wider population, reducing health system burden while improving patient outcomes. The recommendations focus on three areas: (i) establishing a new dynamic national patient registry for clinical trial recruitment; (ii) the use of biomarkers to improve early and accurate diagnosis; and (iii) a framework for end‐to‐end implementation across the landscape of healthcare, research and regulators. A Brain Aging Registry for Biomarkers, Access to trials, Research and Adoption would support recruitment, monitoring, and personalized care. Embedding digital and biomarker innovations into routine care would improve personalized and equitable dementia services, with earlier diagnosis and more effective prevention. Robust patient and public involvement is required, to ensure transparency, trustworthiness, and meaningful participation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chair of the Scientific Advisory Board of the Dementia Goals Programme, Operating Partner of SV Health Investors, London, UK.
- Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
- Informatics & Predictive Sciences, Bristol Myers Squibb, Cambridge, Massachusetts, USA.
- University College London, London, UK.
- Vannin Neuropharma Consulting Ltd, Canterbury, UK.
- Medicines Discovery Catapult, Macclesfield, UK.
ORCID-Profile: James B Rowe
Förderung
- Medical Research Council
- Wellcome Trust
- NIHR Cambridge Biomedical Research Centre
- European Commission (Marie Curie International Training Network
- Innovative Medicines Initiatives 3TR
- EPND
- European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States
- Horizon Europe
Zitieren
APA
McKernan, R. M., Rowe, J. B., John, S., Karran, E., Fachim, H. A., Imarisio, S., Long, R., Teunissen, C., Slight, S. P., Mummery, C., & Hardy, J. (2026). Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71621
Vancouver
McKernan RM, Rowe JB, John S, Karran E, Fachim HA, Imarisio S, et al. Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71621
BibTeX
@article{McKernan2026,
author = {McKernan, Ruth M and Rowe, James B and John, Sally and Karran, Eric and Fachim, Helene A and Imarisio, Sara and Long, Raj and Teunissen, Charlotte and Slight, Sarah P and Mummery, Catherine and Hardy, John},
title = {Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom—Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71621}
}
EUVIMED